← ALNY: big moves and long-term fundamentals中文

Alnylam Pharmaceuticals: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 5, 2026 · Reflects: the 10-K for 2025, the 10-Q for Q3 2026 (filed Oct 29, 2026) and the 8-K filed Nov 5, 2026

Disclosure: one or more of our editors own shares of Alnylam Pharmaceuticals (ALNY) as a long-term investment. This page is information, not investment advice.

Labels: “Disclosed” = stated in a filing or company release; “Our calculation” = arithmetic on disclosed figures (formula in the notes at the end); “Reported” = third-party reporting, not verified by us. Figures in US dollars.

1. In one paragraph

Last updated Nov 5, 2026. Reflects the 10-K for 2025, the 10-Q for Q3 2026 (filed Oct 29, 2026) and the 8-K filed Nov 5, 2026.

Alnylam develops and sells RNA interference (RNAi) medicines, which reduce production of selected proteins by breaking down messenger RNA, the instructions cells use to make them. In 2025 total revenue was $3.71B (Disclosed), and most of it now comes from one drug, Amvuttra (vutrisiran).

  • Amvuttra is an injection given every three months for transthyretin (TTR) amyloidosis, a disease in which a misfolded protein damages the nerves and the heart.
  • Amvuttra was 62% of 2025 revenue; collaboration revenue (mainly Roche) was 15%, including a one-time $300M milestone.
Source of revenue (2025) $M % of revenue (our calculation)1
Amvuttra 2,314 62%
Onpattro (older TTR drug) 173 5%
Givlaari and Oxlumo (rare metabolic diseases) 500 13%
Collaborations (mainly Roche; includes a one-time $300M milestone) 553 15%
Royalties (mainly Novartis’s Leqvio) 174 5%
Total 3,714 100%

Source: Q4 2025 earnings release, 10-K 2025.

Alnylam pays Sanofi a royalty of 15–30% on Amvuttra sales. The top rate applies to annual sales above $1.5B (Disclosed, 10-Q Q2 2026).

2. Story so far

Last updated Nov 5, 2026. Reflects filings and releases to Nov 5, 2026.

In short: Alnylam spent years as a loss-making developer of RNAi drugs for rare diseases, until Amvuttra’s expansion into TTR heart disease, after a 2024 trial and a 2025 approval, drove growth and its first annual profit in 2025, helped by a $300M Roche milestone. In 2026 demand has grown more slowly than management anticipated: it cut TTR sales guidance in July, saying growth from patients switching from stabilizer medicines (pills that help keep the TTR protein from misfolding) had slowed, and said in October that sales would land at the low end of the reduced range; the stock fell 25% that day. In November it authorised its first buyback programme since at least 2021, up to $1.0B, and said its Chief Commercialization Officer would leave; separately, Medicare set a lower 2027 outpatient payment for covered drugs that hospitals buy under the 340B discount programme.

Date Milestone Source
Apr 2020 Sells 50% of its future Leqvio royalties to Blackstone for $1.0B 10-Q Q2 2026, Note 9
Jun 13, 2022 FDA approves Amvuttra for hereditary TTR amyloidosis with nerve damage 10-K 2025
Jul 21, 2023 Roche deal to co-develop zilebesiran for high blood pressure 10-Q Q2 2026, Note 4
Jun 24, 2024 ★ HELIOS-B heart trial of Amvuttra succeeds Company release
Mar 20, 2025 ★ FDA approves Amvuttra for TTR amyloidosis affecting the heart, its biggest market 10-Q Q2 2026
Sep 2025 Issues $661M of 0% convertible notes (debt that holders can exchange for cash, shares or both under set conditions) due 2028 and pays about $1.1B to repurchase $638M principal of the 2027 notes. Recognises a $300M Roche milestone 10-Q Q2 2026, Note 8; Q4 2025 release
Jan 11, 2026 “Alnylam 2030” plan, with a target of at least 25% compound annual revenue growth through 2030; 2026 product-sales guidance of $4.9–5.3B 8-K exhibit
Feb 12, 2026 ★ First full year of profit under US generally accepted accounting principles (GAAP): 2025 net income $314M Q4 2025 release
Jul 9, 2026 Rival AstraZeneca reports that its TTR silencer eplontersen missed its main heart-outcomes goal in a trial where most patients also took stabilizers AstraZeneca release
Jul 30, 2026 ★ Cuts 2026 TTR sales guidance by $200M. Yahoo Finance reports closes of $286.62 on Jul 29 and $205.48 on Jul 30 (Reported), a change of −28.3% (our calculation)2 Q2 2026 release; prices: Yahoo Finance
Oct 27, 2026 Our coverage starts with this Long View —
Oct 29, 2026 Q3 results: guidance reiterated, but the CFO says TTR sales will land at the low end of the range and the CEO says Alnylam is “not yet satisfied with the underlying demand growth”. Nasdaq reports closes of $232.40 on Oct 28 and $174.00 on Oct 29 (Reported), a change of −25.1% (our calculation)3 Q3 2026 release; call transcript, Stock Analysis; prices: Nasdaq historical data
Nov 2, 2026 Board authorises up to $1.0B of share buybacks; Alnylam anticipates about $500M by the end of 2026 and the balance during 2027 Company release, Nov 4, 2026; 8-K, Nov 5, 2026
Nov 4, 2026 Medicare finalises its 2027 hospital outpatient payment for separately payable drugs bought under 340B: average sales price minus 28%, against plus 6% now, with some hospital types exempt CMS fact sheet
Nov 4, 2026 Alnylam says Chief Commercialization Officer Tolga Tanguler will leave in December Company release, Nov 4, 2026; 8-K, Nov 5, 2026

3. Latest quarter: did the story change?

Last updated Nov 5, 2026. Reflects Q3 2026 (quarter to Sep 30, 2026), release and 10-Q, both Oct 29, 2026, and the call.

Bottom line: In Q3 2026 Amvuttra sales rose again and Alnylam reiterated its 2026 guidance, but the CFO said TTR sales would land at the low end of the range. US demand grew less than in Q2, part of the quarter’s gain came from inventory and one-off price adjustments, and two early data readouts moved to February 2027 (Q3 release; call).

Driver Last quarter → this quarter Management: before → now Signal
US Amvuttra sales $809M → $909M 2026 TTR sales guidance: $4.2–4.5B (cut Jul 30) → $4.2–4.5B reiterated, at the low end, the CFO said (Oct 29) Better
US TTR demand growth from the prior quarter +$129M → +$81M. Q3 sales were also helped by a $17M inventory benefit and about $10M of favourable gross-to-net (rebate and discount) adjustments Q2: demand growth offset by inventory and a modest price cut → Q3: inventory and price adjustments added to growth; both expected to be headwinds in Q4 (Disclosed; CFO on the call, Reported) Watch
Amvuttra outside the US $203M → $222M No outlook change disclosed → growth driven by heart-disease launches in Japan, Germany and Italy and by the timing of partner orders (Disclosed) Better
Cost of goods sold as % of product sales 25.4% → 28.0% Same explanation → higher blended Sanofi royalty rate as Amvuttra sales grow (Disclosed) Worse
Pipeline timing ALN-6400 Phase 2 data in hereditary hemorrhagic telangiectasia and ALN-2232 Phase 1 obesity data: 2H 2026 → with Q4 results in February 2027; ALN-6400 healthy-volunteer data remain scheduled for December 2026. The nucresiran heart trial grows again, from 1,750 to about 2,250 patients, with launch still expected by 2030 2H 2026 (Jul 30) → February 2027 (Oct 29) Watch

What it means: sales grew, but the outlook softened. Landing at $4.2B would take about $1.11B of Q4 TTR sales, about $40M below Q3 (our calculation).4 The CFO’s reasons: a larger sales force isn’t yet producing demand at the pace expected, so the outlook assumes “no material top-line contribution” from it in 2026; hospitals may change their ordering ahead of the 340B rule; and UnitedHealth has restricted first-line use in Medicare Advantage (section 6). He also noted that $4.2B would still be nearly 70% growth on last year. The CEO said “we do not expect acceleration of growth in Q4 2026” (call transcript, Stock Analysis; Reported). Reported net income of $2.17B includes a $1.9B tax benefit from recognising previously reserved US tax benefits that the company now expects to use against future taxable income; that is an accounting gain, not cash.

Unresolved questions: whether US demand growth recovers from the Q3 pace; how hospitals respond to the 340B rule; and the outcome of Alnylam’s patent suit against Cipla, which has asked the FDA to approve a generic version of Amvuttra.

4. Buybacks vs real dilution (5 years)

Last updated Nov 5, 2026. Reflects 10-K 2023, 10-K 2025 and 10-Q Q3 2026 (statements of stockholders’ equity), XBRL company facts, and the 8-K filed Nov 5, 2026.

Dilution in one line: shares outstanding rose 13.7% from Dec 31, 2020 to Dec 31, 2025 (2.6% a year, compounded). If you owned 1% of Alnylam at the end of 2020, you’d own 0.88% at the end of 2025 without buying more (our calculation)5. Buybacks offset 0% of the new shares. Our scale: Moderate (1–3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Dec 31, 2025FY2021 +3.2%, FY2022 +3.1%, FY2023 +1.5%, FY2024 +2.8%, FY2025 +2.4%. Total +13.7% since Dec 31, 2020.0%+5%+10%+15%FY2021: +3.2% in the period; +3.2% since Dec 31, 2020+3.2%FY2021FY2022: +3.1% in the period; +6.4% since Dec 31, 2020+3.1%FY2022FY2023: +1.5% in the period; +8.0% since Dec 31, 2020+1.5%FY2023FY2024: +2.8% in the period; +11.1% since Dec 31, 2020+2.8%FY2024FY2025: +2.4% in the period; +13.7% since Dec 31, 2020+2.4%FY2025+13.7%since Dec 31, 2020

Change in the period Total since Dec 31, 2020

Shares outstanding at period end (all classes): 116.4M on Dec 31, 2020, 132.4M on Dec 31, 2025, +13.7% (our calculation). A bar below zero means the count fell (net buybacks).

Latest quarter-end (Jun 30, 2026): 133.7M shares, +1.0% since Dec 31, 2025.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 31, 2025)132.4M+2.4%—$348M9%
FY2024 (Dec 31, 2024)129.3M+2.8%—$272M12%
FY2023 (Dec 31, 2023)125.8M+1.5%—$222M12%
FY2022 (Dec 31, 2022)123.9M+3.1%—$231M22%
FY2021 (Dec 31, 2021)120.2M+3.2%—$166M20%
FY2020 (Dec 31, 2020)116.4M——$140M28%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

Alnylam has not bought back stock in 2021–2025, so every new share adds to the count: all of the growth came from employee stock options and awards.

  • The equity statements show no shares issued through stock offerings, acquisitions or note conversions.
  • The 2025 cash repurchases of notes were accounted for as induced conversions, an accounting treatment for deals that encourage noteholders to convert early.

New since the quarter: a buyback programme. In November the board authorised up to $1.0B of repurchases, the first programme since at least 2021. Alnylam anticipates about $500M by the end of 2026 and the balance during 2027, though the timing and amount depend on the share price, its capital needs and other uses for the money, and it can change or stop the programme at any time without notice (8-K). The board says the share price “does not fully reflect Alnylam’s intrinsic value”, and the company says repurchases will run alongside continued investment in the heart launch, the pipeline and selective outside innovation (company release).

At the Nov 5 close of $156.66 (Yahoo Finance; Reported), $1.0B would buy about 6.4M shares, about 4.8% of those outstanding: just under two years of dilution at the 2020–2025 pace (our calculation).6 The trade-off is cash: $1.0B is about 28% of the $3.59B of cash, cash equivalents and marketable securities Alnylam held at Sep 30 (section 5).

How we calculated this
Share bridge (millions) 2021 2022 2023 2024 2025 5-yr total
Start of year 116.4 120.2 123.9 125.8 129.3 116.4
+ Options exercised 3.0 3.1 1.2 2.5 1.8 11.6
+ Other equity plans (restricted stock units, employee stock purchases) 0.8 0.6 0.7 1.0 1.2 4.4
− Shares repurchased 0 0 0 0 0 0
End of year 120.2 123.9 125.8 129.3 132.4 132.4
Stock-based pay, % of revenue (our calculation)7 19.6% 22.2% 12.1% 12.1% 9.4%

Stock-based pay and revenue: both Disclosed (10-K 2023, 10-K 2025).

  • Shares outstanding increased by 16.0M over 2021–2025, or 13.7% (about 2.6% a year; our calculation)8. Rounded table entries may not add exactly.
  • Diluted weighted-average shares rose from 114.986M in 2020 to 134.684M in 2025 (Disclosed), an increase of 17.1% (our calculation)9. Sources: 2020 10-K and Q4 2025 release.
  • This measure also changes with accounting: loss years exclude potential shares that profitable years include, so the bridge above is the better measure of shares actually issued.
  • In 2026 so far, shares outstanding rose from 132.4M (Dec 31, 2025) to 133.9M (Sep 30, 2026), about 1.1% in nine months, again only from employee equity plans (our calculation)10. There were 133.9M shares on Oct 23, 2026 (10-Q Q3 2026 cover).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 — — — — — — 10-K 2023, statement of stockholders’ equity
2022 — — — — — — 10-K 2023, statement of stockholders’ equity
2023 — — — — — — 10-K 2023 and 10-K 2025, statements of stockholders’ equity
2024 — — — — — — 10-K 2025, statement of stockholders’ equity
2025 — — — — — — 10-K 2025, statement of stockholders’ equity
2026 YTD (to Sep 30) — — — — — — 10-Q Q3 2026, statement of stockholders’ equity

Alnylam made no share buybacks and no share offerings or at-the-market sales in 2021 through September 2026, so the table has no entries. The $1.0B programme came after that period; purchases will appear here once Alnylam reports them. Its convertible notes could add shares in future.

Notes on the prices table, convertible notes and trading plans
  • Shares withheld for employee taxes (option exercises are shown net of tax withholding) are excluded.
  • The 2025 cash repurchases of convertible notes were debt repurchases, not share buybacks.
  • Alnylam has no stock splits in the period, so no split adjustment applies.
  • Stock options and other equity plans brought in about $1.21B of net cash over 2021–2025 (our calculation)11.
  • Convertible notes could cause future dilution: notes of $362.8M due 2027 (conversion price $286.20) and $661.3M due 2028 ($670.11). Alnylam may settle conversions in cash, shares or both.
  • It also bought capped calls, contracts meant to offset conversion dilution up to $424 and $837.61 a share (Disclosed, Note 8).
  • The buyback may be carried out in the open market, including under pre-arranged trading plans (Rule 10b5-1), or in privately negotiated deals. It has no expiration date and doesn’t oblige Alnylam to buy any amount (8-K).
  • Pre-arranged executive share-sale plans (Rule 10b5-1): Tanguler adopted a plan in August for up to 22,438 shares, with sales from late November 2026 (10-Q Q3 2026).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 5, 2026. Reflects 10-K 2025, 10-Qs and releases to Q3 2026, and the 8-K filed Nov 5, 2026. TTM = four quarters to Sep 30, 2026.

In the 12 months to September, net income ($2.65B) far exceeded operating cash flow ($956M) because a $1.87B non-cash tax benefit in Q3 went through profit. Without that benefit, net income would be about $780M, below operating cash flow (our calculation).12

In 2025, operating cash flow exceeded GAAP net income: stock-based pay and non-cash Blackstone interest were added back, while growth in receivables absorbed cash. Company-adjusted net income exceeded operating cash flow, and the one-time Roche milestone contributed to both profit and cash.

$M 2025 TTM to Sep 202613
Net income under US accounting rules (GAAP) 314 2,649
Company-adjusted net income (non-GAAP; excludes stock pay, specified investment gains and losses and the note-repurchase loss, with tax adjustments; does not exclude the Q3 2026 tax benefit) 684 2,937
Operating cash flow 524 956
Capital spending (59) (150)
Free cash flow (cash from operations after capital spending; our calculation)14 465 806

Helps future profit or cash:

  • Receivables (+$360M growth in 2025): sales are in profit but not yet collected, so the cash arrives when customers pay.

Hurts future profit or cash:

  • Stock-based pay ($348M in 2025): a real cost paid in shares rather than cash; it adds no cash outflow but dilutes ownership, and it is why non-GAAP profit is higher than GAAP profit.
  • Blackstone royalty and funding deals ($238M of interest accrued in 2025, added back as non-cash): cash payments recorded as interest ($118M on the Leqvio deal and $85M on development funding in 2025) are already inside operating cash flow and continue under the deals.

One-off / no lasting effect:

  • The $300M Roche milestone is in 2025 profit and will not recur on its own.
  • A $42M loss on the convertible-note buyback is excluded from non-GAAP profit.
  • The $1.87B Q3 2026 income tax benefit, mainly a $1.95B release of a reserve against past tax benefits (a valuation allowance). It brings in no cash, and it’s in both GAAP and company-adjusted net income.
The raw reconciling items

Disclosed, 10-K 2025 cash-flow statement and release reconciliation:

  • Stock-based pay ($348M in 2025) is a real cost, paid in shares rather than cash. That is why non-GAAP profit is higher than GAAP profit.
  • Interest on the Blackstone royalty and funding deals ($238M accrued in 2025) is added back in the cash-flow statement as non-cash. The company says cash payments to Blackstone recorded as interest ($118M on the Leqvio deal and $85M on development funding in 2025) are included in operating cash flow.
  • Receivables grew by $360M in 2025 as sales rose, so less of the year’s profit had arrived as cash.
  • One-off items: 2025 profit includes the $300M Roche milestone, and non-GAAP profit also excludes a $42M loss on the convertible-note buyback.
Self-funding

Funding: how long without new money? Self-funding: $806M of free cash flow in the 12 months to Sep 30, 2026 (our calculation)15; $362.8M of convertible notes fall due in Sep 2027 and $661.3M in Sep 2028, against $3.59B of cash, cash equivalents and marketable securities. The new buyback would use up to $1.0B of that by the end of 2027 if completed as Alnylam anticipates.

Funding details
  • This is based on past cash flow; spending plans can change it.
  • Capital spending rose to $126M in the first nine months of 2026, from $35M a year earlier (Disclosed), as Alnylam expands manufacturing.
  • Sources: 10-Q Q3 2026, Notes 8–9, balance sheet and cash-flow statement; 8-K, Nov 5, 2026.
  • No at-the-market share-sale programme is disclosed.

Extends the runway:

  • Undrawn credit: a $500M revolving credit facility with no borrowings ($17.5M of letters of credit outstanding) at Sep 30, 2026.

Shortens the runway:

  • Share buybacks: up to $1.0B authorised Nov 2, 2026, with about $500M anticipated by the end of 2026 and the balance during 2027. Alnylam can slow or stop them. With the $362.8M of notes due in Sep 2027, that’s about 38% of cash, cash equivalents and marketable securities at Sep 30, before any cash generated in between (our calculation).16
  • Debt due within 24 months: $362.8M of 1% convertible notes on Sep 15, 2027 (now shown as a current liability); the $661.3M of 0% notes follow on Sep 15, 2028.
  • Blackstone development-funding payments continue under instalment schedules, alongside a 1% royalty on vutrisiran sales (Note 9).

Conditional:

  • Specified regulatory approvals for zilebesiran would trigger $243M payable to Blackstone in 16 equal quarterly instalments over four years (Disclosed, Note 9).

6. Customer and contract exposure

Last updated Nov 5, 2026. Reflects 10-K 2025, 10-Q Q3 2026, the Q3 call and the CMS final rule (Nov 4, 2026).

Alnylam discloses heavy customer concentration: one unnamed distributor accounted for 45% of gross revenue in 2025. The distributor concentration creates credit and distribution exposure. Alnylam also identifies insurer reimbursement, including Medicare, as a sales risk (10-K 2025).

Who pays is the nearer pressure. Amvuttra is “reimbursed predominantly under Medicare Part B”, so Alnylam says changes to that payment policy could affect it more than a drug with a different mix (10-Q Q3 2026, new this quarter). Two changes came this autumn, and Alnylam has given no dollar figure for either.

  • 340B payment cut. Hospitals in the federal 340B programme buy drugs at a discount. From January 2027, Original Medicare’s hospital outpatient payment for separately payable drugs bought under 340B falls from average sales price plus 6% to minus 28%; it had proposed minus 33.4%. Rural sole community hospitals, cancer hospitals exempt from Medicare’s prospective payment system, and children’s hospitals are exempt. This changes what covered hospitals receive; it doesn’t directly set Alnylam’s price (CMS; American Hospital Association). The Centers for Medicare & Medicaid Services (CMS), which runs Medicare, says its survey found large differences between hospitals’ costs for drugs bought through 340B and those bought outside it, and that the cut aligns payment more closely with those costs. It estimates that patients’ drug payments fall by $1.1B in the first year; payments for hospitals’ non-drug services rise 7.5% to offset the cut. Ashley Thompson, American Hospital Association senior vice president, called it a “continued assault on the 340B program”.
  • What it means for Alnylam. A “meaningful portion” of US Amvuttra units is bought under 340B (10-Q), and the CFO wouldn’t be more specific. Speaking before the final rule, he said the effect on net price depends on what hospitals do: staying in 340B purchasing would push it down, because Alnylam would be discounting below the current 340B price, while moving to regular purchasing or sending patients to outside clinics or home would help it. On volume: “We don’t know that yet.” Before the final rule, Alnylam anticipated legal challenges from hospital groups (call transcript, Stock Analysis; Reported). Our search on Nov 5, 2026 found no announced lawsuit against this payment rule; a hospital suit filed in October concerns a separate 340B rebate programme (American Hospital Association).
  • Medicare Advantage limits. Certain of these privately run Medicare plans have made Amvuttra non-preferred, so patients must try another drug first (10-Q, new this quarter). UnitedHealth’s more restrictive first-line policy took effect Oct 1. Alnylam says it’s “not expected to impact existing patients” and that exceptions exist, but it “could create some delays for new patients”. The 2026 outlook includes an expected impact (call transcript, Stock Analysis; Reported).
Customers at or above 10% of Alnylam gross revenue
Distributor A, 2023: 28% of gross revenueDistributor A, 202328%Distributor A, 2024: 29% of gross revenueDistributor A, 202429%Distributor A, 2025: 45% of gross revenueDistributor A, 202545%Roche, 2023: 15% of gross revenueRoche, 202315%Regeneron, 2024: 11% of gross revenueRegeneron, 202411%
Show the data
Label Value Unit
Distributor A, 2023 28 % of gross revenue
Distributor A, 2024 29 % of gross revenue
Distributor A, 2025 45 % of gross revenue
Roche, 2023 15 % of gross revenue
Regeneron, 2024 11 % of gross revenue

Chart source17.

Customers ≥10% of gross revenue (Disclosed, 10-K 2025) 2023 2024 2025
Distributor A (not named) 28% 29% 45%
Roche 15% <10% <10%
Regeneron <10% 11% <10%

Distributor A also accounted for 45% of gross accounts receivable at Dec 31, 2025. “<10%” includes entities that were not customers in that year.

Alnylam shares Amvuttra’s economics with Sanofi and Blackstone, and zilebesiran’s development costs and potential commercial economics with Roche; some partners can end their deals on notice (Disclosed):

Key contract and legal details
  • Sanofi receives tiered royalties of 15–30% on Amvuttra sales. The experimental successor, nucresiran, carries no Sanofi royalty but still needs successful trials and approval.
  • Roche generally funds 60% of zilebesiran development supporting global approval. Extra US-only development is split equally, and Roche funds work mainly for its own territory. The two companies split US profits 50/50, and Roche can end the deal for any reason on written notice.
  • Novartis pays Alnylam royalties on Leqvio and can end the agreement on four months’ notice.
  • Blackstone receives 50% of Leqvio royalties, potentially rising to 55% from 2030 if it has received less than $1B by the end of 2029. A separate development-funding agreement requires milestone payments and a 1% royalty on vutrisiran sales for 10 years from the first sale after the heart-disease approval; it is secured on related intellectual property and a funding account (10-Q Q1 2026, Note 9).
  • Regeneron’s exclusive research period with Alnylam ended in May 2026; programmes already nominated continue.
  • A subpoena from the US Attorney in Massachusetts (Oct 2025) covers government price reporting for all four Alnylam products. Alnylam says it has produced records and continues to engage with that office. It reported no material loss contingencies accrued as of Sep 30, 2026 (10-Q Q3 2026, Note 12).
  • Patent suits (10-Q Q3 2026, Note 12): Alnylam has sued Cipla over its proposed generic versions of Amvuttra and, with Novartis and The Medicines Company, of Leqvio; it warns that generic Amvuttra could materially reduce its sales. Separately, the University of Texas alleges that Onpattro infringes one of its patents; trial is scheduled for August 2027.
  • Pricing pilot: Medicare’s GLOBE pilot, as finalised, doesn’t apply to medicines indicated only for orphan (rare-disease) uses, and Alnylam anticipates no impact (10-Q Q3 2026).
  • FDA letter: Alnylam says the FDA closed out its April objection to content on Amvuttra’s consumer website in August, after the company responded (10-Q Q3 2026).
  • Tariffs: a 100% US tariff on imported patented medicines took effect by Sep 29, 2026, subject to exemptions and reduced rates. Alnylam relies on contract manufacturers and warns that tariffs may raise its cost of goods; it gives no estimate (10-Q Q3 2026).

7. Alnylam’s strategy for long-term growth

Last updated Nov 5, 2026. Reflects the Jan 11, 2026 “Alnylam 2030” release, the 10-Q for Q3 2026, the Nov 4 company release, the Q3 call and Pfizer’s 10-Q for Q2 2026.

Alnylam’s plan is to lead the TTR market by revenue, extend that lead with a successor drug, and use the cash to build new medicines. Ten months in, sales are growing quickly, but its largest near-term goal has been cut and the leader of its commercial team is leaving. Management says the 2030 goals stand.

Pressure on the core business

  • Competing pills: Pfizer’s Vyndaqel/Vyndamax and BridgeBio’s Attruby are taken by mouth and have lower US list prices than Amvuttra, which Alnylam says may hurt its share and revenue (10-Q Q3 2026). Generic Vyndamax capsules can launch in the US from June 1, 2031, subject to other litigation (Pfizer 10-Q).
  • Payment: the 340B cut and Medicare Advantage limits (section 6).
  • Patents: Cipla’s proposed generic Amvuttra (section 6).
  • Cost: Sanofi’s royalty rate rises with Amvuttra sales, which lifted cost of goods to 28.0% of product sales in Q3 (section 3).

The strategy, in management’s words

“Alnylam 2030” is built on “achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility” (January release). Its near-term tactic is a larger sales force to reach more prescribers. It budgets for “select external innovation”, but the Q3 10-Q describes no acquisition; its one recent deal there is a research collaboration with Inceptive, an artificial-intelligence (AI) company, including $15M of preferred stock.

How it’s working, in numbers

Target for 2030 (set Jan 2026) Latest Source
At least 25% compound annual revenue growth through 2030 Revenue up 50% in the first nine months of 2026, to $3.92B (our calculation),18 which isn’t the compound rate for the full period. Asked by Luca Issi, RBC Capital Markets analyst, whether the target looked optimistic, CEO Yvonne Greenstreet pointed to about 75,000 treated US heart-disease patients by 2030, a third of US TTR prescriptions, current pricing assumptions and continued growth outside the US Q3 release; call transcript, Stock Analysis
Lead the TTR market in revenue 24% of total US TTR prescriptions and more than 30% of new-to-brand prescriptions (patients starting a particular medicine). 2026 TTR guidance: $4.4–4.7B in January → $4.2–4.5B in July → low end in October. Market revenue ranking: not disclosed call transcript, Stock Analysis; January release
Launch nucresiran in nerve disease by 2028 and heart disease by 2030 Both Phase 3 trials are running, with no results yet. The heart trial has grown from 1,250 to about 2,250 patients; Alnylam still expects a heart launch by 2030 10-Q Q3 2026
Two or more new medicines beyond TTR None yet. Brezosiran: pivotal study planned for 2027, pending regulatory alignment. Zilebesiran (with Roche) is in Phase 3 10-Q Q3 2026
10 tissue types and more than 40 clinical programmes More than 25 clinical programmes beyond TTR. Tissue count: not disclosed call transcript, Stock Analysis
About 30% of revenue in non-GAAP research and development (R&D) 25.8% in Q3 2026 (our calculation)18 Q3 release
About 30% non-GAAP operating margin 29.1% in Q3 2026 (our calculation)18 Q3 release

Setbacks so far

  • The TTR guidance cut in July and the low-end comment in October (above).
  • Tanguler, who presented the launch figures on the Q3 call, leaves in December. Alnylam gives no reason for his departure and says a search firm is helping select his successor; none had been announced by Nov 5, 2026.
  • Regeneron opted out of co-developing mivelsiran in May 2024, leaving Alnylam with the full rights and costs. An early Alzheimer’s study of the drug remains on partial FDA hold at certain doses; Alnylam says development hasn’t been affected (10-Q Q3 2026).

What to watch: section 8.

8. What to watch

Last updated Nov 5, 2026. Reflects the Q3 2026 release, 10-Q and call (Oct 29, 2026), the 8-K filed Nov 5, 2026 and the CMS final rule.

Date Item Source
Nov 2026 FDA target action date for Regeneron’s cemdisiran in generalized myasthenia gravis; if approved, Alnylam is eligible for tiered royalties of up to 15% on sales Q3 2026 release
Nov 6–9, 2026 Two-year open-label extension results from the HELIOS-B heart trial of Amvuttra (American Heart Association meeting) Q3 2026 release
Nov 15–18, 2026 Indirect comparison of Amvuttra with BridgeBio’s acoramidis (International Symposium on Amyloidosis) Q3 2026 release
Nov 20, 2026 Givlaari’s US orphan-drug exclusivity ends; selected listed US patents expire between 2028 and 2034, before possible extensions 10-K 2025
Dec 12–15, 2026 ALN-6400 healthy-volunteer data (American Society of Hematology meeting) Q3 2026 release
Dec 2026 Tanguler leaves; the search for a successor, and the terms of his departure, due in a written agreement by his separation date 8-K; company release
Jan 2027 340B payment cut takes effect, unless a court challenge changes it CMS
Jan 2027 Preliminary Q4 and full-year 2026 revenue at the JPMorgan conference; 2027 guidance moves to February, after more time to assess 340B Call
Mid-Feb 2027 Q4 2026 results with 2027 product revenue guidance, the first read on 340B and how much of the buyback was done; also ALN-6400 (hereditary hemorrhagic telangiectasia) and ALN-2232 (obesity) data Call; Q3 2026 release
Aug 2027 University of Texas patent trial over Onpattro 10-Q Q3 2026, Note 12
Sep 15, 2027 $362.8M of 1% convertible notes mature 10-Q Q3 2026, Note 8

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 27, 2026$226.79 (Oct 27)$30.3B$28.0B6.3×5.8×39.1×37.0×+95%17%$2.3B12 months to Jun 30, 2026
Oct 29, 2026$174.00 (Oct 29)$23.3B$20.7B†4.6×4.1×8.8×*28.9×+56%16%$2.6B†12 months to Sep 30, 2026
Nov 5, 2026$156.66 (Nov 5)$21.0B$18.4B†4.2×3.7×7.9×*26.0×+56%16%$2.6B†12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 29, 2026: * Trailing P/E includes a $1.9B one-off tax benefit (release of a valuation allowance). † Debt excludes ~$1.735B of royalty and development-funding liabilities (Blackstone/Sixth Street), which the company reports separately. Nov 5, 2026: * Trailing P/E includes a $1.9B one-off tax benefit (release of a valuation allowance). † Debt excludes ~$1.735B of royalty and development-funding liabilities (Blackstone/Sixth Street), which the company reports separately. Oct 27, 2026 price: official close, Nasdaq historical quotes. Oct 29, 2026 price: official close, Nasdaq. Nov 5, 2026 price: official close, Yahoo and CNBC.

Notes and calculations

  1. Each line ÷ total revenue. ↩

  2. ($205.48 ÷ $286.62 − 1) × 100. ↩

  3. ($174.00 ÷ $232.40 − 1) × 100. ↩

  4. Nine-month TTR sales were $3,090.6M (Disclosed, 10-Q). Q4 needed for the $4.2B low end = $4,200M − $3,090.6M = $1,109.4M, about $41M below Q3’s $1,150.0M. ↩

  5. 116.4M ÷ 132.4M. ↩

  6. $1,000M ÷ $156.66 = 6.38M shares; ÷ 133.94M shares (10-Q cover, Oct 23) = 4.8%; 4.8% ÷ 2.6% a year (see “Dilution in one line”) ≈ 1.8 years. $1,000M ÷ $3,587M = 28%. ↩

  7. Stock-based compensation ÷ total revenue. ↩

  8. On unrounded counts: cumulative growth = end ÷ start − 1; yearly = (end ÷ start)^(1/5) − 1. ↩

  9. 134.684 ÷ 114.986 − 1. ↩

  10. 133.875M ÷ 132.376M − 1 (statements of stockholders’ equity, 10-K 2025 and 10-Q Q3 2026). ↩

  11. Sum of the cash-flow statement’s yearly “proceeds from exercise of stock options and other types of equity, net”. ↩

  12. $2,649M − $1,872M (Q3 2026 benefit from income taxes) = $777M. ↩

  13. TTM = 2025 + first nine months of 2026 − first nine months of 2025 (our calculation). Company-adjusted net income, $M = 683.644 + 273.038 + 251.801 + 2,241.910 − 37.941 − 38.171 − 437.779 (2025, plus 2026’s first three quarters, less 2025’s first three quarters; quarterly releases) = 2,936.502, rounded to 2,937. ↩

  14. Operating cash flow − capital spending. ↩

  15. TTM operating cash flow $956M − capital spending $150M; each = 2025 + first nine months of 2026 − first nine months of 2025 (OCF 524 + 738 − 306; capex 59 + 126 − 35). ↩

  16. ($1,000M + $362.8M) ÷ $3,587M. ↩

  17. Alnylam 10-K 2025, customers at or above 10% of gross revenue (Disclosed). ↩

  18. Nine-month revenue $3,916M ÷ $2,617M − 1. Q3 2026: non-GAAP R&D $375.7M ÷ revenue $1,458.1M; non-GAAP operating income $424.9M ÷ revenue $1,458.1M. ↩ ↩2 ↩3

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Alnylam Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)